Business
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common
About this update from Trevi Therapeutics, Inc.
[{"type":"image","alt":"Trevi Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Trevi Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":178,"url":"https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bm0hDKDh2VccPo04yMe8oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0OQ--/https://media.zenfs.com/en/globenewswire.com/c14a2e1b9a13526379b2ef57e4bfacf2","width":300,"height":178}},"lazy":false},{"type":"text","content":"NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. In addition, Trevi has granted the underwriters a 30-day option to purchase up to 1,740,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 20, 2026, subject to satisfaction of customary closing conditions.","length":1083,"tagName":"p"},{"type":"text","content":"Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering and Oppenheimer & Co. is acting as lead manager.","length":164,"tagName":"p"},{"type":"text","content":"The shares are being offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-291517), which was filed with the Securities and Exchange Commission (SEC) on November 13, 2025 and became effective automatically upon filing. This offering is being made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of th...